Cor Vasa 2026, 68(Suppl.1):30-38

2025 cílená aktualizace doporučení ESC/EAS z roku 2019 pro léčbu dyslipidemií

Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS, Michal Vrablík^a, Martin Šatný^a, Miloš Táborský^b

^a III. interní klinika - klinika endokrinologie a metabolismu, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika

^b Kardiologická klinika Fakulty zdravotnických studií Univerzity J. E. Purkyně v Ústí nad Labem a Krajské zdravotní, a.s. - Masarykovy nemocnice v Ústí nad Labem, o.z., Ústí nad Labem, Česká republika

The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC warns readers that the technical language may be misinterpreted and declines any responsibility in this respect. Translated by the Czech Society of Cardiology, the ESC cannot be held liable for the content of this translated document. © 2026 European Society of Cardiology. All rights reserved. Published by the Czech Society of Cardiology. For permissions: please e-mail: guidelines@escardio.org The material was translated from the "2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias"

Received: April 1, 2026; Accepted: April 1, 2026; Prepublished online: June 2, 2012; Published: May 8, 2026  Show citation